HomeCompareMKGAF vs QYLD

MKGAF vs QYLD: Dividend Comparison 2026

MKGAF yields 2.04% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MKGAF wins by $112.8K in total portfolio value
10 years
MKGAF
MKGAF
● Live price
2.04%
Share price
$122.45
Annual div
$2.50
5Y div CAGR
52.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.2K
Annual income
$57,634.11
Full MKGAF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — MKGAF vs QYLD

📍 MKGAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKGAFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKGAF + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKGAF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKGAF
Annual income on $10K today (after 15% tax)
$173.61/yr
After 10yr DRIP, annual income (after tax)
$48,988.99/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, MKGAF beats the other by $44,178.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKGAF + QYLD for your $10,000?

MKGAF: 50%QYLD: 50%
100% QYLD50/50100% MKGAF
Portfolio after 10yr
$81.8K
Annual income
$31,646.72/yr
Blended yield
38.70%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKGAF buys
0
QYLD buys
0
No recent congressional trades found for MKGAF or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKGAFQYLD
Forward yield2.04%11.92%
Annual dividend / share$2.50$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR52.7%0%
Portfolio after 10y$138.2K$25.4K
Annual income after 10y$57,634.11$5,659.31
Total dividends collected$109.9K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: MKGAF vs QYLD ($10,000, DRIP)

YearMKGAF PortfolioMKGAF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$11,012$311.88$10,352$1,192.36+$660.00MKGAF
2$12,273$490.13$10,830$1,347.57+$1.4KMKGAF
3$13,912$779.56$11,460$1,539.07+$2.5KMKGAF
4$16,146$1,261.05$12,275$1,777.84+$3.9KMKGAF
5$19,365$2,088.77$13,323$2,078.95+$6.0KMKGAF
6$24,296$3,575.17$14,667$2,463.34+$9.6KMKGAF
7$32,398$6,401.21$16,396$2,960.57+$16.0KMKGAF
8$46,847$12,181.47$18,631$3,612.97+$28.2KMKGAF
9$75,264$25,137.47$21,548$4,482.15+$53.7KMKGAF
10$138,167$57,634.11$25,398$5,659.31+$112.8KMKGAF

MKGAF vs QYLD: Complete Analysis 2026

MKGAFStock

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Full MKGAF Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this MKGAF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKGAF vs SCHDMKGAF vs JEPIMKGAF vs OMKGAF vs KOMKGAF vs MAINMKGAF vs XYLDMKGAF vs JEPQMKGAF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.